Jeffrey L. Alvaro, M.D., introduces an upcoming panel discussion surrounding the clinical implications of novel drug delivery systems in the management of Pediatric ADHD, utilizing 3 patient cases.
SDX/d-MPH safe and effective against pediatric ADHD
March 15th 2023In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).
ADHD medications do not significantly increase cardiovascular disease risk
January 16th 2023A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.